-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target

Benzinga·05/28/2026 13:31:07
Listen to the news
Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.